NSE · Basic Materials · Specialty Chemicals
EPS came in at 6.33 against a street estimate of 8.80 — a miss of 28.1%.
with an average price target of ₹610.50.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 ROSSARI BIOTECH LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated Revenue: Rs 697.2 crore (Q1 FY27), up 28.2% YoY from Rs 543.7 crore (Q1 FY | 2026-07-19 |
| Annual report FY2026 ROSSARI BIOTECH LIMITED ANNUAL REPORT 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from operations: ₹23,963.65 million (FY 2 | 2026-06-27 |
| Investor presentation · Q4 FY26 ROSSARI BIOTECH LIMITED – Q4 & FY26 RESULTS SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 2,396.4 cr (up 15.2% YoY from Rs. 2,080.3 cr in FY25) • FY2 | 2026-04-28 |
| Investor presentation · Q3 FY26 ROSSARI BIOTECH LIMITED – Q3 & 9M FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue from Operations: Rs 581.7 crore (up 13% YoY vs Rs 512.7 cr | 2026-01-18 |
| Investor presentation · Q2 FY26 ROSSARI BIOTECH LIMITED – Q2 & H1 FY26 SUMMARY HEADLINE NUMBERS • Q2 FY26 Revenue: Rs. 586.1 crore (up 18% year-on-year, up 8% quarter-on-quarter) • | 2025-10-16 |
| Investor presentation | 2025-07-20 |
| Annual report FY2025 ROSSARI BIOTECH LIMITED – FY2024-25 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹20,802.94 million (FY2024: ₹18,305.58 million) – growth of | 2025-06-06 |
| Investor presentation | 2025-04-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.50 / share ex-date Jul 10, 2026 | 2026-07-10 |
| Announcement | Date |
|---|---|
| Capacity addition update announced at subsidiary facility Update on Capacity Addition at the Subsidiary. | 2026-03-31 |
| Update on capacity addition by company and subsidiary Update on Capacity Addition by the Company and at the Subsidiary. | 2025-09-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rossari Biotech Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.